我们能改变患有充血性心力衰竭的患者的生存率吗?
1Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Md. 21205.
JAMA
|April 8, 1992
概括
对充血性心力衰竭 (CHF) 的药理疗法可以改善存活率,特别是使用血管激素转化酶抑制剂. 死亡率仍然是评估新型心血管疾病药物治疗的关键终点.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 充血性心力衰竭 (CHF) 的管理是复杂的,正在研究有效的药物治疗方法.
- 评估药物在CHF的疗效需要仔细考虑终点,特别是患者的存活率.
研究的目的:
- 评估药理疗法在改善充血性心力衰竭 (CHF) 患者的生存率方面的有效性.
- 分析最近的研究,其中死亡率是CHF药物干预的主要终点.
主要方法:
- 从MEDLINE数据库中对英语文章进行系统审查,包括随机和回顾性研究.
- 纳入标准侧重于以死亡率为主要或次要终点的研究.
- 数据质量通过研究规模,设计 (随机,双盲) 和统计有效性等标准进行评估.
主要成果:
- 一些改善血液动力学或在CHF中提高运动耐受性的药物药物不一定会延长存活时间.
- ангиотензин转化酶 (ACE) 抑制剂在有症状的慢性心血管疾病患者中显示出改善的生存率,以及增强的运动能力和左心室功能.
- 与氨酸化物和异索二酸盐的联合治疗也显示出生存益处,尽管在较小程度上比ACE抑制剂.
结论:
- 死亡率是确定药理治疗在充血性心力衰竭 (CHF) 疗效的关键终点.
- 需要进一步进行大规模,随机,双盲研究,以最终评估新的CHF药理学药物的生存益处.
更多相关视频
相关概念视频
01:30Heart Failure V: Medical Management
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
01:22Heart Failure VI: Adjunct Therapies
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
01:30Heart Failure VII: Nursing Interventions
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
01:30Cardiomyopathy II: Dilated Cardiomyopathy
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
01:29Cardiomyopathy V: Interprofessional Care
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
01:29Cardiomyopathy VI: Nursing Management
Assessment: Nursing management of patients with cardiomyopathy begins with a thorough assessment of the patient's history, including a family history of cardiomyopathy or sudden cardiac death, personal history of heart disease, hypertension, diabetes, and any alcohol consumption or drug use.During the physical examination, assess vital signs, look for signs of heart failure (such as edema, jugular venous distention, and cyanosis), auscultate for abnormal heart sounds (like murmurs and gallops),...